Holen Sie sich die Stockscreener-App
17.39
1.34%
0.23
Handel nachbörslich:
17.12
-0.27
-1.55%
Schlusskurs vom Vortag:
$17.16
Offen:
$17.25
24-Stunden-Volumen:
1.04M
Relative Volume:
0.34
Marktkapitalisierung:
$1.09B
Einnahmen:
$16.10M
Nettoeinkommen (Verlust:
$-198.97M
KGV:
-4.9958
EPS:
-3.4809
Netto-Cashflow:
$-183.99M
1W Leistung:
+18.06%
1M Leistung:
+21.86%
6M Leistung:
-67.13%
1J Leistung:
+94.08%
1-Tages-Spanne:
$16.85
$17.69
1-Wochen-Bereich:
$15.04
$17.69
52-Wochen-Spanne:
$7.76
$71.50
Uniqure N V Stock (QURE) Company Profile
Firmenname
Uniqure N V
Sektor
Branche
Telefon
1-339-970-7000
Adresse
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
17.39 | 1.07B | 16.10M | -198.97M | -183.99M | -3.4809 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-11 | Hochstufung | Mizuho | Neutral → Outperform |
| 2026-03-09 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-03-09 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2026-03-03 | Herabstufung | Mizuho | Outperform → Neutral |
| 2026-03-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2026-03-02 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2026-03-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-02-24 | Eingeleitet | Wolfe Research | Peer Perform |
| 2026-01-28 | Eingeleitet | Barclays | Equal Weight |
| 2025-11-04 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-08-14 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-04-01 | Fortgesetzt | Chardan Capital Markets | Buy |
| 2024-12-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-02-29 | Herabstufung | Goldman | Buy → Neutral |
| 2023-12-19 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-17 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-21 | Eingeleitet | UBS | Neutral |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-01 | Hochstufung | Mizuho | Neutral → Buy |
| 2021-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-11-11 | Eingeleitet | Berenberg | Buy |
| 2020-11-09 | Eingeleitet | Jefferies | Buy |
| 2020-11-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-08-25 | Eingeleitet | Raymond James | Strong Buy |
| 2020-07-31 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-06-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Eingeleitet | Cowen | Outperform |
| 2019-12-03 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Eingeleitet | Credit Suisse | Outperform |
| 2019-10-11 | Eingeleitet | Stifel | Buy |
| 2019-09-25 | Eingeleitet | Bernstein | Outperform |
| 2019-09-12 | Eingeleitet | Mizuho | Buy |
| 2019-07-30 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-07-08 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-03-29 | Eingeleitet | Robert W. Baird | Outperform |
Alle ansehen
Uniqure N V Aktie (QURE) Neueste Nachrichten
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm - prnewswire.com
QURE Investors Have Opportunity to Lead uniQure N.V. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
UniQure NV (NASDAQ:QURE) Q4 2025 earnings call transcript - MSN
ROSEN, A LEADING NATIONAL FIRM, Encourages Trip.com Group Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
UNIQURE DEADLINE: ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages uniQure N.V. Investors ... - Caledonian Record
UNIQURE DEADLINE: ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages uniQure N.V. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 13 Deadline in Securities Class Action - GlobeNewswire Inc.
INO FINAL DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Inovio Pharmaceuticals Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action – INO - GlobeNewswire Inc.
UniQure used 'distorted comparison' in Huntington's asset trial: FDA official - msn.com
uniQure Faces FDA Rebuke as Shareholder Class Action Filed - Intellectia AI
(QURE) Movement as an Input in Quant Signal Sets - Stock Traders Daily
QURE 9-DAY DEADLINE ALERT: Hagens Berman Updates uniQure - GlobeNewswire
QURE SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 - prnewswire.com
Aberdeen Group plc Acquires 738,897 Shares of uniQure N.V. $QURE - MarketBeat
uniQure Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against uniQure N.V.QURE - Sahm
uniQure N.V. (NASDAQ:QURE) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
uniQure N.V. Class Action Reminder - National Today
uniQure N.V. Class Action Reminder – Robbins LLP Encourages QURE Stockholders to Contact the Firm fo - PharmiWeb.com
uniQure N.V. Class Action Reminder – Robbins LLP Encourages QURE Stockholders to Contact the Firm for Information About Their Rights - The Daily Tribune News
FinancialContentuniQure N.V. Class Action Reminder – Robbins LLP Encourages QURE Stockholders to Contact the Firm for Information About Their Rights - FinancialContent
QURE ALERT: Hagens Berman Updates uniQure (QURE) Probe After FDA Criticism; April 13 Deadline Nears - prnewswire.com
UniQure surges following departure of key FDA official - MSN
QURE Deadline: QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit - Sahm
uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock DeclineInvestors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC - accessnewswire.com
UNIQURE DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages uniQure N.V. Investors to Secure ... - Caledonian Record
UNIQURE DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages uniQure N.V. Investors to Secure Counsel Before Important April 13 Deadline in Securities Class Action - GlobeNewswire Inc.
UNIQURE DEADLINE APPROACHING: Bragar Eagel & Squire, P.C. - globenewswire.com
Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
UNIQURE N.V. (QURE) SHAREHOLDER ALERT Bernstein Liebhard - globenewswire.com
2026-04-02 | QURE SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 | NDAQ:QURE | Press Release - Stockhouse
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming DeadlinesQURE - prnewswire.com
uniQure (QURE) Loses 67.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Eastern Progress
Barclays reaffirms equal weight rating for uniQure (QURE) - MSN
Levi & Korsinsky Reminds uniQure N.V. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 13, 2026QURE - prnewswire.com
Rare disease advocacy group urges Trump administration to restore FDA clarity - MarketScreener
Barclays Reaffirms Equal Weight Rating for uniQure (QURE) - Insider Monkey
uniQure Investors File Class Action Lawsuit Over FDA Approval Delay - Intellectia AI
uniQure N.V. Securities Fraud Class Action Result of FDA - globenewswire.com
QURE jumps 20% – analysts upgrade stock on Huntington’s disease therapy update, retail eyes $150 - MSN
Hemophilia B Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Pfizer, Spark Therapeutics, Sanofi, Alnylam Pharma, CSL Behring, uniQure, Novo Nordisk - Barchart.com
QURE Shareholder Alert: uniQure N.V. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm - prnewswire.com
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Deadline Approaching for uniQure N.V. Class Action Lawsuit - National Today
Contact Levi & Korsinsky by April 13, 2026 Deadline to Join Class Action Against uniQure N.V. (QURE) - GlobeNewswire
QURE SHAREHOLDER NOTICE: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data - PR Newswire
uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz - gurufocus.com
uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP: Investors Face April 13, 2026, Deadline - PR Newswire
March 2026: Pharmacological advancements in rare diseases - The Pharma Letter
uniQure N.V. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsQURE - ChartMill
QURE DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 - ChartMill
Rosen Law Firm Encourages uniQure Investors to Secure Counsel Before Deadline - National Today
ROSEN Firm Encourages uniQure Investors to Secure Counsel - National Today
Finanzdaten der Uniqure N V-Aktie (QURE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Uniqure N V-Aktie (QURE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Abi-Saab Walid | Chief Medical Officer |
Mar 04 '26 |
Sale |
9.06 |
808 |
7,320 |
189,669 |
| Potts Jeannette | Chief Legal Officer |
Mar 04 '26 |
Sale |
9.06 |
3,412 |
30,913 |
138,483 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Mar 04 '26 |
Sale |
9.06 |
12,000 |
108,720 |
226,581 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):